Treatment
Daunorubicin clinical trials
We’re tracking 54 recruiting studies that include Daunorubicin, each written for real people, not researchers, below.
Recruiting studies
- NCT06124157RecruitingPhase 2
Targeted therapy plus chemo for children with Ph+ or Ph-like B-ALL
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Birmingham, AlabamaAges 1 year–46 years - NCT06533748RecruitingPhase 2
New treatment for kids with B-cell leukemia or lymphoma
This trial tests a new therapy plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia or lymphoma. It aims to improve outcomes for those with higher-risk features.
Charlotte, North CarolinaAges 1–18 - NCT06390319RecruitingPhase 2
Adding dasatinib or venetoclax for children with T-cell leukemia or lymphoma
This trial tests whether adding either dasatinib or venetoclax to standard chemotherapy can improve outcomes for children aged 1 to 18 with newly diagnosed T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. It compares the effects of these added drugs to help doctors find better treatment options.
San Diego, CaliforniaAges 1–18 - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Birmingham, AlabamaAges 12 months–25 years - NCT03643276RecruitingPhase 3
Study of treatment plans for children with leukemia
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
SydneyAges Up to 17 years - NCT03896269RecruitingPhase 1
CPX-351 for high-risk MDS or CMML that came back
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
Houston, TexasAges 18 years+ - NCT06289673RecruitingPhase 4
Collecting info to start treatment for new leukemia or lymphoma
This study gathers key health information at the start of treatment for children and teens newly diagnosed with certain types of leukemia or lymphoma. The goal is to find the best way to begin therapy right away, without waiting for extra tests.
San Diego, CaliforniaAges 1–18 - NCT04043494RecruitingPhase 3
Study of new treatment plans for childhood lymphoblastic lymphoma
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
GrazAges Up to 18 years - NCT04049539RecruitingPhase 1/Phase 2
Vyxeos for AML that stays after initial chemotherapy
This trial tests whether Vyxeos (a type of chemotherapy) can treat acute myeloid leukemia (AML) that did not fully go away after standard induction (“7+3”) chemotherapy. It targets people whose leukemia is still present in the bone marrow and need a stronger “re-induction” treatment.
Sacramento, CaliforniaAges 18–75 - NCT04385290RecruitingPhase 1/Phase 2
Testing midostaurin plus gemtuzumab for newly diagnosed AML
This trial studies whether combining two medicines—midostaurin and gemtuzumab (with standard chemotherapy)—can improve outcomes for newly diagnosed acute myeloid leukemia (AML). It is testing a first-line treatment plan tailored to specific genetic changes in the leukemia.
München, BavariaAges 18–75 - NCT04440267RecruitingPhase 2
Tested leukemia treatment for mixed-type acute leukemia
This Phase 2 study tests a leukemia-based treatment for people with acute leukemia that doesn’t clearly belong to one type. It aims to improve outcomes for patients who meet specific health and heart/lab requirements.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT04493164RecruitingPhase 2
CPX-351 plus ivosidenib for IDH1-mutated leukemia or high-risk MDS
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
Houston, TexasAges 18 years+ - NCT04659616RecruitingPhase 1
Pemigatinib after standard chemo for newly diagnosed AML
This Phase 1 trial studies whether adding pemigatinib after standard “7+3” chemotherapy can improve outcomes in certain newly diagnosed acute myeloid leukemia (AML) patients. It aims to find a safe dose and see how well the drug works in a very specific AML genetic group.
Portland, OregonAges 18 years+ - NCT05342584RecruitingPhase 1
Venetoclax plus intensive chemo for AML and advanced MDS
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
The Bronx, New YorkAges 18–75 - NCT05627232RecruitingPhase 1
Tazemetostat and palbociclib for relapsed or resistant AML
This early-phase study tests whether tazemetostat and palbociclib can help people with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It looks for safety and early signs of how well the treatment works.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05660473RecruitingPhase 2
Study of venetoclax plus chemotherapy for Ph-negative ALL
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
TianjinAges 14–60 - NCT05726110RecruitingPhase 3
Selinexor for relapsed or refractory AML in combination treatments
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
Taiyuan, ShanxiAges 18–60 - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Phoenix, ArizonaAges 18 years+ - NCT05939180RecruitingPhase 2/Phase 3
Compare two induction treatments for newly diagnosed high-risk AML
This trial tests whether one initial chemotherapy approach works better than another in people newly diagnosed with high-risk acute myeloid leukemia (AML). You may benefit if your disease is high-risk, and the study will also compare how well the treatments control the leukemia and how safely they work.
Suzhou, JiangsuAges 18–64 - NCT05959720Recruiting
Teen-to-adult ALL study using a pediatric chemotherapy plan
This trial tests a treatment plan for newly diagnosed acute lymphoblastic leukemia (ALL) in people ages 16 to 50. It aims to see how well a “pediatric-style” regimen works, but it only fits certain genetic and health profiles.
São Paulo, São PauloAges 16–50 - NCT06313437RecruitingPhase 1
Revumenib with 7+3 and midostaurin for AML
This trial tests a new drug called revumenib combined with a strong chemotherapy regimen (7+3) and midostaurin for people with newly diagnosed AML that has specific gene mutations (FLT3 and NPM1). The goal is to see if this combination works better than standard treatments.
New Haven, ConnecticutAges 18–75 - NCT06345365RecruitingPhase 3
MA+AZA for Newly Diagnosed AML
This trial tests a combination of two medicines (called MA+AZA) for people who have just been diagnosed with acute myeloid leukemia (AML). It aims to see if this treatment can help control the disease and improve outcomes.
Zhengzhou, HenanAges 18–75 - NCT06635681RecruitingPhase 2
Venetoclax plus intensive chemo for AML subtypes
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT06918431RecruitingPhase 2
Erwinia asparaginase with chemo for new ALL or LBL
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
Phoenix, ArizonaAges 18–54
Common questions
- Are there clinical trials studying Daunorubicin?
- Yes. Clin2 currently lists 54 recruiting studies that include Daunorubicin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Daunorubicin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Daunorubicin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Daunorubicin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.